Treatment of established atherosclerosis during cholesterol feeding in monkeys.
A semipurified diet containing 43% of the calories as fat and 1.2 mg of cholesterol/cal was fed to cynomolgus monkeys (Macaca fascicularis) for 6 months; the cholesterol content was reduced to 0.34 mg/cal for the next 18 months. During the latter period, the monkeys were assigned to 4 groups of 18 animals each and received the following dietary additions: A, none (controls); B, cholestyramine (5%, w/w); C, dextrothyroxine (0.003%); and D, Wy-14,643 (0.45%). Cholestyramine normalized plasma lipid levels and reduced the size of aortic and coronary atherosclerotic lesions in spite of the high-fat, high-cholesterol intake. Dextrothyroxine reduced cholesterolemia but did not modify the extent of arterial lesions. Wy-14,643 changed neither plasma cholesterol levels nor the extent of atherosclerosis.
D000085:Acetates; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001011:Aorta / Q000473:pathology; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D003331:Coronary Vessels / Q000473:pathology; D003918:Dextrothyroxine / Q000627:therapeutic use*; D005260:Female; D000882:Haplorhini; D008074:Lipoproteins / Q000097:blood; D008252:Macaca fascicularis; D010743:Phospholipids / Q000097:blood; D011743:Pyrimidines / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000085:Acetates; D000924:Anticholesteremic Agents; D002791:Cholesterol, Dietary; D008074:Lipoproteins; D010743:Phospholipids; D011743:Pyrimidines; D014280:Triglycerides; D002792:Cholestyramine Resin; D003918:Dextrothyroxine; C006253:pirinixic acid; D002784:Cholesterol